Amyotrophic lateral sclerosis (ALS) is a devastating disease of motor neurons with unknown etiology. Evidence suggests that the brain undergoes degenerative changes in ALS, particularly within areas of the descending motor pathway. Identifying robust and non-invasive biomarkers that are sensitive to neurodegeneration in ALS is essential for improving clinical trial design and assessment of treatment effectiveness. This study evaluated 1H-MRS-measured metabolite levels as biomarkers of disease severity. Ultra-high field (7 tesla) 1H-MRS revealed metabolic abnormalities in the motor cortex and brainstem of humans with ALS that are dependent on disease stage.
This abstract and the presentation materials are available to members only; a login is required.